Type 2 diabetes therapy: Ipsen is currently testing an innovative sustained release formulation of its GLP-1 analogue based on its proprietary drug delivery system technologies

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria